Edwards Lifesciences
875 hedge funds and large institutions have $27.1B invested in Edwards Lifesciences in 2018 Q4 according to their latest regulatory filings, with 123 funds opening new positions, 252 increasing their positions, 336 reducing their positions, and 93 closing their positions.
32% more first-time investments, than exits
New positions opened: 123 | Existing positions closed: 93
3% more funds holding
Funds holding: 852 → 875 (+23)
2.37% more ownership
Funds ownership: 251.8% → 254.17% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 23 → 23 (0)
3% less call options, than puts
Call options by funds: $120M | Put options by funds: $124M
11% less capital invested
Capital invested by funds: $30.6B → $27.1B (-$3.46B)
25% less repeat investments, than reductions
Existing positions increased: 252 | Existing positions reduced: 336
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$405M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$258M |
| 3 |
BlackRock
New York
|
+$171M |
| 4 |
Legal & General Group
London,
United Kingdom
|
+$167M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$136M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$214M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$109M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$94.3M |
| 4 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$80.4M |
| 5 |
O
OrbiMed
New York
|
-$79.7M |
EW Hedge Fund Activity: Q4 2018 in Review
875 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2018, worth a combined $27.1B — down 11% from $30.6B a quarter earlier.
Buyers outnumbered sellers: 123 funds opened new EW positions and 93 closed out — a net gain of 30 holders — while 252 added to existing stakes and 336 trimmed.
The largest buyer was Jennison Associates, adding an estimated $405M. The largest seller was Winslow Capital Management, cutting an estimated $214M.
- 875 institutional investors held Edwards Lifesciences (EW) as of Q4 2018, up from 852 in Q3 2018.
- Funds reported $27.1B of Edwards Lifesciences stock for Q4 2018, down 11% quarter-over-quarter.
- 123 funds opened new Edwards Lifesciences positions in Q4 2018 and 93 closed out, a net change of +30 holders.
- The largest Edwards Lifesciences buyer in Q4 2018 was Jennison Associates, an estimated $405M added.
- The largest Edwards Lifesciences seller in Q4 2018 was Winslow Capital Management, an estimated $214M sold.
Based on aggregated 13F filings for Q4 2018.